SCHEMBL5509535

SCHEMBL5509535

CN(C)OCCOC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AMD1 P17707 2/20 0.66
AHCY P23526 3/20 0.66
NADK O95544 1/20 0.66
ADORA1 P30542 3/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
DOT1L Q8TEK3 2/20 0.65
ADORA3 P0DMS8 2/20 0.65
ADORA2A P29274 2/20 0.65
ADORA2B P29275 2/20 0.65
DPP4 P27487 1/20 0.65
MEN1 O00255 1/20 0.65
SLC28A1 O00337 1/20 0.65
MAP3K7 O43318 1/20 0.65
SLC28A2 O43868 1/20 0.65
GAPDH P04406 1/20 0.65
MAPK1 P28482 1/20 0.65
STAT6 P42226 1/20 0.65
PI4KA P42356 1/20 0.65
KMT2A Q03164 1/20 0.65
PI4K2B Q8TCG2 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8328542 0.93 ADORA1 (0.74) AMD1AHCYNADKADORA1SMN1; SMN2
SCHEMBL5964927 0.91 AHCY (0.72) AMD1AHCYNADKADORA1SMN1; SMN2
SCHEMBL4581742 0.90 P2RY1 (0.70) AMD1AHCYNADKADORA1SMN1; SMN2
SCHEMBL2534140 0.89 EHMT1 (0.70) AMD1AHCYNADKADORA1SMN1; SMN2
SCHEMBL6828798 0.88 ADORA1 (0.70) AHCYNADKADORA1SMN1; SMN2DOT1L
SCHEMBL2270709 0.88 ADORA1 (0.73) AHCYNADKADORA1SMN1; SMN2DOT1L
SCHEMBL29936475 0.87 EHMT1 (0.74) AHCYNADKADORA1SMN1; SMN2DOT1L
SCHEMBL8671037 0.87 EHMT1 (0.74) AHCYNADKADORA1SMN1; SMN2DOT1L
SCHEMBL8671033 0.87 EHMT1 (0.74) AHCYNADKADORA1SMN1; SMN2DOT1L
SCHEMBL10786307 0.87 ADORA1 (0.72) AHCYNADKADORA1SMN1; SMN2DOT1L

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0977767-B1 AMINOOXY-MODIFIED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS INC (US) 2007-09-19 EP disclosed
US-6624294-B2 Dissolving nucleoside in solvent to form a solution; cooling; treating with base; warming; reacting with ester to effect alkylation of 2' position of a 2',3'-dihydroxy sugar moiety of a nucleoside ISIS PHARMACEUTICALS, INC. 2003-09-23 US disclosed
EP-0977767-A4 AMINOOXY-MODIFIED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS INC (US) 2003-04-23 EP disclosed
EP-1102783-A4 AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM ISIS PHARMACEUTICALS INC (US) 2002-07-31 EP disclosed
US-6403779-B1 DISSOLVING NUCLEOSIDE IN APROTIC SOLVENT, COOLING, TREATING WITH BASE, WARMING MIXTURE, COOLING, REACTING WITH REACTIVE ESTER TO EFFECT ALKYLATION ISIS PHARMACEUTICALS, INC. 2002-06-11 US disclosed
EP-1102783-A1 AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 2001-05-30 EP disclosed
US-6194598-B1 Aminooxy-modified oligonucleotide synthetic intermediates ISIS PHARMACEUTICALS, INC. 2001-02-27 US disclosed
US-6172209-B1 MOLECULAR HYBRIDIZATION, GENETIC ENGINEERING; NUCLEASE RESISTANCE ISIS PHARMACEUTICALS INC. 2001-01-09 US disclosed
US-6127533-A SPECIFICALLY HYBRIDIZABLE WITH A SELECTED SEQUENCE OF RNA OR DNA; DIAGNOSIS OF DISEASES ISIS PHARMACEUTICALS, INC. (US) 2000-10-03 US disclosed
WO-2000008042-A1 AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 2000-02-17 WO disclosed
EP-0977767-A1 AMINOOXY-MODIFIED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2000-02-09 EP disclosed
WO-1998035978-A9 AMINOOXY-MODIFIED OLIGONUCLEOTIDES 1999-01-14 WO disclosed
WO-1998035978-A1 AMINOOXY-MODIFIED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 1998-08-20 WO disclosed